Dramatic response to infliximab in refractory neurosarcoidosis

Annals of Indian Academy of Neurology

Volumn 13, Issue 3, 2010, Pages 207-210

  Chintamaneni, Sreekanth ^a   Patel, Aarat M ^a   Pegram, Samuel B ^b   Patel, Hirenkumar ^a   Roppelt, Heidi ^a  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^b Medical Clinic of Houston   (United States)

Author keywords

Infliximab; neurosarcoidosis; tumor necrosis factor

Indexed keywords

DEXAMETHASONE; INFLIXIMAB; PENTOXIFYLLINE; PREDNISONE;

ADULT; ARTICLE; BRAIN DAMAGE; CASE REPORT; DRUG DOSE INCREASE; HEMISPHERE; HUMAN; HUMAN TISSUE; MALE; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; RELAPSE; SARCOIDOSIS;

EID: 77958087834     PISSN: 09722327     EISSN: 19983549     Source Type: Journal    
DOI: 10.4103/0972-2327.70874     Document Type: Article

References (19)

1. th ed. Philadelphia: Elsevier Saunders; 2005. p. 1705-17.
2. Zajicek JP, Scolding NJ, Foster O, Rovaris M, Evanson J, Moseley IF, et al. Central nervous system sarcoidosis-diagnosis and management. QJM 1999;92:103-17.
3. Judson MA. The etiologic agent of sarcoidosis What if there isn't one? Chest 2003;124:6-8.
4. Kunkel SL, Chensue SW, Strieter RM, Lynch JP, Remick DG. Cellular and molecular aspects of granulomatous infl ammation. Am J Respir Cell Mol Biol 1989;1:439-47.
5. Ziegenhagen MW, Müller-Quernheim J. The cytokine network in sarcoidosis and its clinical relevance. J Intern Med 2003;253: 18-30.
6. Baughman RP, Strohofer SA, Buchsbaum J, Lower EE. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med 1990;115:36-42.
7. Müller-Quernheim J, Pfeifer S, Männel D, Strausz J, Ferlinz R. Lung-restricted activation of the alveolar macrophage/monocyte system in pulmonary sarcoidosis. Am Rev Respir Dis 1992;145:187-92.
8. Ziegenhagen MW, Rothe ME, Zissel G, Müller-Quernheim J. Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002;19:185-90.
9. Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A. Etanercept for refractory ocular sarcoidosis: Results of a double-blind randomized trial. Chest 2005;128:1062-7.
10. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infl iximab. Chest 2005;127:1064-71.
11. Pettersen JA, Zochodne DW, Bell RB, Martin L, Hill MD. Refractory neurosarcoidosis responding to infl iximab. Neurology 2002;59:1660-1.
12. Clinicaltrials.gov website A Service of the U.S. National Institutes of Health. Available from: http://www.clinicaltrials.gov/ct2/results? term=adalimumab+and+sarcoidosis. [accessed on 2008 Nov 13].
13. Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-Pavlovic Z, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003;124:177-85.
14. Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, Du Bois R, et al. Infl iximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006;174:795-802.
15. Judson MA, Baughman RP, Costabel U, Flavin S, Lo KH, Kavuru MS, et al. Efficacy of infl iximab in extrapulmonary sarcoidosis: Results from a randomised trial. Eur Respir J 2008;31:1189-96.
16. Sollberger M, Fluri F, Baumann T, Sonnet S, Tamm M, Steck AJ, et al. Successful treatment of steroid-refractory neurosarcoidosis with infl iximab. J Neurol 2004;251:760-1.
17. Kumar G, Kang CA, Giannini C. Neurosarcoidosis presenting as a cerebellar mass. J Gen Intern Med 2007;22:1373-76.
18. Carter JD, Valeriano J, Vasey FB, Bognar B. Refractory neurosarcoidosis: A dramatic response to infl iximab. Am J Med 2004;117:277-9.
19. Haraoui B. Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin Arthritis Rheum 2005;34:7-11.